A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Δ24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy

International Journal of Molecular Medicine

Volumn 18, Issue 4, 2006, Pages 751-759

  Hakkarainen, Tanja ^a,b,c   Hemminki, Akseli ^b,c   Curiel, David T ^d   Wahlfors, Jarmo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cancer gene therapy; Green fluorescent protein; HSV TK; Oncolytic adenovirus; Prodrug suicide gene therapy; Viral spreading

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL; ARTICLE; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOUSE; MOUSE STRAIN; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; FEMALE; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, INBRED STRAINS; MICE, NUDE; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; RECOMBINANT FUSION PROTEINS; THYMIDINE KINASE; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33947400151     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.18.4.751     Document Type: Article

References (43)

1. Volpers C and Kochanek S: Adenoviral vectors for gene transfer and therapy. J Gene Med 6 (Suppl 1): S164-S171, 2004.
2. Kootstra NA and Verma IM: Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol 43: 413-439, 2003.
3. Sinkovics J and Horvath J: New developments in the virus therapy of cancer: A historical review. Intervirology 36: 193-214, 1993.
4. Martuza RL, Malick A, Markert JM, Ruffner KL and Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856, 1991.
5. Fueyo J, Gomez-Manzano C, Alemany R, et al: A mutant oncolytic adenovirus targeting the rb pathway produces antiglioma effect in vivo. Oncogene 19: 2-12, 2000.
6. Kirn D, Martuza RL and Zwiebel J: Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7: 781-787, 2001. (Pubitemid 32691631)
7. Bauerschmitz GJ, Barker SD and Hemminki A: Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). Int J Oncol 21: 1161-1174, 2002.
8. Wildner O, Blaese RM and Morris JC: Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 59: 410-413, 1999. (Pubitemid 29048876)
9. Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ and Blaese RM: Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 6: 57-62, 1999.
10. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM and Gerritsen WR: Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 62: 6165-6171, 2002.
11. Freytag SO, Stricker H, Pegg J, et al: Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63: 7497-7506, 2003.
12. Fuerer C and Iggo R: 5-fluorocytosine increases the toxicity of wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene. Gene Ther 11: 142-151, 2004.
13. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD and Kim JH: A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 9: 1323-1333, 1998.
14. Lambright ES, Amin K, Wiewrodt R, et al: Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther 8: 946-953, 2001. (Pubitemid 32600151)
15. Morris JC and Wildner O: Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ther 1: 56-62, 2000.
16. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH and Freytag SO: Double suicide gene therapy augments the anti-tumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 11: 67-76, 2000.
17. Wildner O and Morris JC: The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res 60: 4167-4174, 2000. (Pubitemid 30636600)
18. Le LP, Everts M, Dmitriev IP, Davydova JG, Yamamoto M and Curiel DT: Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging 3: 105-116, 2004.
19. Contag CH, Spilman SD, Contag PR, et al: Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem Photobiol 66: 523-531 1997.
20. Gambhir SS, Barrio JR, Wu L, et al: Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med 39: 2003-2011, 1998.
21. Loimas S, Wahlfors J and Janne J: Herpes simplex virus thymidine kinase-green fluorescent protein fusion gene: new tool for gene transfer studies and gene therapy. Biotechniques 24: 614-618, 1998.
22. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
23. Hakkarainen T, Wahlfors T, Merilainen O, Loimas S, Hemminki A and Wahlfors J: VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct. J Gene Med 7: 898-907, 2005.
24. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT and Alemany R: A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 7: 120-126, 2001. (Pubitemid 32110214)
25. Kanerva A, Zinn KR, Chaudhuri TR, et al: Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 8: 449-458, 2003.
26. Khuri FR, Nemunaitis J, Ganly I, et al: a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-885, 2000.
27. Lamfers ML, Grill J, Dirven CM, et al: Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 62: 5736-5742, 2002.
28. Reid T, Galanis E, Abbruzzese J, et al: Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res 62: 6070-6079, 2002.
29. Rogulski KR, Freytag SO, Zhang K, et al: In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 60: 1193-1196, 2000.
30. Chen MJ, Green NK, Reynolds GM, et al: Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther 11: 1126-1136, 2004.
31. Haviv YS, Takayama K, Glasgow JN, Blackwell JL, Wang M, Lei X and Curiel DT: A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene. Mol Cancer Ther 1: 321-328, 2002.
32. Hemminki A, Wang M, Hakkarainen T, Desmond RA, Wahlfors J and Curiel DT: Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential. Cancer Gene Ther 10: 583-588, 2003.
33. Rivera AA, Wang M, Suzuki K, Uil TG, Krasnykh V, Curiel DT and Nettelbeck DM: Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. Virology 320: 121-134, 2004.
34. Kanerva A, Mikheeva GV, Krasnykh V, et al: Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 8: 275-280, 2002.
35. Post DE and Van Meir EG: A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 22: 2065-2072, 2003.
36. Bi WL, Parysek LM, Warnick R and Stambrook PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 4: 725-731, 1993.
37. Mesnil M, Piccoli C, Tiraby G, Willecke K and Yamasaki H: Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 93: 1831-1835, 1996.
38. Kanerva A and Hemminki A: Modified adenoviruses for cancer gene therapy. Int J Cancer 110: 475-480, 2004.
39. Kokoris MS, Sabo P, Adman ET and Black ME: Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther 6: 1415-1426, 1999.
40. Black ME, Kokoris MS and Sabo P: Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 61: 3022-3026, 2001.
41. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A and Smitt PS: Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 61: 8743-8750, 2001.
42. Chipman JK, Mally A and Edwards GO: Disruption of gap junctions in toxicity and carcinogenicity. Toxicol Sci 71: 146-153, 2003.
43. Kanerva A, Zinn KR, Peng KW, et al: Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther 12: 87-94, 2005.